Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEOD001 + bortezomib
- Development stage
- Discontinued
- Lead developer
- Prothena
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
**NEOD001 + bortezomib** is an investigational combination therapy for amyloid light-chain (AL) amyloidosis. NEOD001 (also known as birtamimab) is a humanized IgG1 monoclonal antibody targeting a conserved epitope in misfolded κ and λ light chains, designed to neutralize toxic soluble light chain aggregates and promote macrophage-induced phagocytosis of organ-deposited insoluble amyloid. Bortezomib is a small molecule proteasome inhibitor that disrupts plasma cell function and reduces amyloidogenic free light chains. The combination seeks to both suppress production of amyloidogenic light chains (via bortezomib) and directly clear existing amyloid deposits (via NEOD001)[1][4]. NEOD001 was developed specifically for AL amyloidosis; bortezomib is widely used in myeloma and amyloidosis and is a standard backbone in current treatment regimens.
- Other names
- birtamimab + bortezomib
02
Targets
PSMB9 (Immunoproteasome subunit beta type-1i)AL (Amyloid light-chain protein)PSMB1 (26S Proteasome (β1-Subunit))PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on NEOD001 + bortezomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEOD001 + bortezomib.